TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours

BACKGROUND: Despite the effectiveness of imatinib mesylate (IM), most gastrointestinal stromal tumours (GISTs) develop IM resistance, mainly due to the additional kinase-domain mutations accompanied by concomitant reactivation of KIT tyrosine kinase. Heat-shock protein 90 (HSP90) is one of the chape...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Yurina, Takahashi, Tsuyoshi, Obata, Yuuki, Nishida, Toshirou, Ohkubo, Shuichi, Nakagawa, Fumio, Serada, Satoshi, Fujimoto, Minoru, Ohkawara, Tomoharu, Nishigaki, Takahiko, Sugase, Takahito, Koh, Masahiro, Ishida, Tomo, Tanaka, Koji, Miyazaki, Yasuhiro, Makino, Tomoki, Kurokawa, Yukinori, Nakajima, Kiyokazu, Yamasaki, Makoto, Hirota, Seiichi, Naka, Tetsuji, Mori, Masaki, Doki, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054534/
https://www.ncbi.nlm.nih.gov/pubmed/31857719
http://dx.doi.org/10.1038/s41416-019-0688-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054534/
https://www.ncbi.nlm.nih.gov/pubmed/31857719
http://dx.doi.org/10.1038/s41416-019-0688-y

Ejemplares similares